1. Altenergy
2. TradeChem
3. ChemCritique
4. lopopclvp1nv3poo
5. corrosivedeath
1.Altenergy 09/12/2017
Bank of America Merrill Lynch Global Healthcare Conference
2.E3attendee 02/01/2018
Misses EPS estimates by $0.14. Slightly misses on revenues.
3.corrosivedeath 01/30/2018
Confirms the EMA's CHMP adopted a positive opinion recommending a label variation for KYPROLIS to include u…
4.corrosivedeath 06/28/2018
Amgen And Novartis Present New Data Demonstrating Long-Term Efficacy, Safety And Tolerability Of Aimovig™ (erenumab-aooe) In Patients With Chronic And Episodic Migraine
5.lopopclvp1nv3poo 02/13/2018
Amgen says it's looking hard for acquisitions that make sense,
6.memnoch4109 05/15/2018
Mizuho Securities sets PT at $200
7.ChemCritique 04/03/2018
European Commission Approves Expanded Indication For Amgen's XGEVA® (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma
8.TradeChem 09/12/2017
@Altenergy Got you! One sec.  TradeChem Clicking thumbs up, bookmarking, and following me are all ways of saying, "Hey, thanks!" and is much appreciated!  
9.ChemCritique 10/25/2017
Revenue decline but tops expectations
10.corrosivedeath 03/26/2018
Amgen Receives Positive CHMP Opinion Recognizing That Repatha® (evolocumab) Prevents Heart Attacks And Strokes
NEW since the last time you visited this board.
Currently a TOP 10 POST for this board.
Currently a TOP 5 RESEARCHER for this board.
Specific post has replies to it.
A Researcher you are currently FOLLOWING
Other Researchers rate this post HIGH
Other Researchers rate this post LOW